HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PIEZO1
piezo type mechanosensitive ion channel component 1 (Er blood group)
Chromosome 16 Β· 16q24.3
NCBI Gene: 9780Ensembl: ENSG00000103335.23HGNC: HGNC:28993UniProt: Q92508
266PubMed Papers
22Diseases
0Drugs
120Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
positive regulation of integrin activationpositive regulation of cell-cell adhesion mediated by integrinendoplasmic reticulummechanosensitive monoatomic cation channel activitydehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edemalymphedema, hereditary, iiilymphatic malformation 6dehydrated hereditary stomatocytosis
✦AI Summary

PIEZO1 is a mechanosensitive cation channel that serves as a crucial mechanotransducer across multiple organ systems 1. The channel functions as a pore-forming subunit of homotrimeric mechanically activated channels that sense mechanical forces and convert them into cellular responses through calcium influx 2. PIEZO1 exhibits rapid inactivation properties, which are essential for proper mechanosensation and whose disruption leads to various pathologies 3. In vascular systems, PIEZO1 acts as a shear-stress sensor promoting endothelial cell organization and regulating angiogenesis through downstream signaling pathways including HIF-1Ξ± and VEGF 4. In lymphatic vessels, PIEZO1 serves as an upstream mechanosensor that regulates flow-activated lymphatic expansion through ORAI1-mediated mechanotransduction 5. In cartilage, mechanical overloading activates PIEZO1, leading to calcium influx and GPX4-regulated ferroptosis in chondrocytes, contributing to osteoarthritis progression 67. Clinically, PIEZO1 mutations cause dehydrated hereditary stomatocytosis and lymphatic malformations, while its therapeutic modulation shows promise for treating osteoarthritis and lymphedema 75. The channel's widespread distribution and diverse physiological roles make it an important therapeutic target for mechanopathologies 8.

Sources cited
1
PIEZO1 is a mechanosensitive ion channel with essential roles in cardiovascular, lung, urinary, and immune functions
PMID: 34781417
2
PIEZO1 and PIEZO2 function as mechanically activated cation channels with high mechanosensitivity
PMID: 39251883
3
PIEZO channels exhibit rapid inactivation properties essential for proper mechanosensation
PMID: 37762415
4
PIEZO1 promotes angiogenesis through HIF-1Ξ± and VEGF signaling pathways in response to matrix stiffness
PMID: 36181398
5
PIEZO1 serves as upstream mechanosensor for lymphatic expansion through ORAI1-mediated mechanotransduction
PMID: 35701867
6
Mechanical overloading induces GPX4-regulated chondrocyte ferroptosis via PIEZO1-facilitated calcium influx
PMID: 36328754
7
PIEZO1 activation accelerates osteoarthritis progression and can be targeted therapeutically
PMID: 37758057
8
PIEZO1 inhibitors are being developed as therapeutic targets for various pathological processes
PMID: 38761789
Disease Associationsβ“˜22
dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edemaOpen Targets
0.82Strong
lymphedema, hereditary, iiiOpen Targets
0.78Strong
lymphatic malformation 6Open Targets
0.77Strong
dehydrated hereditary stomatocytosisOpen Targets
0.56Moderate
Varicose veinsOpen Targets
0.51Moderate
Non-immune hydrops fetalisOpen Targets
0.46Moderate
genetic disorderOpen Targets
0.46Moderate
vein disorderOpen Targets
0.43Moderate
hydrops fetalisOpen Targets
0.37Weak
hypothyroidismOpen Targets
0.36Weak
Thickened nuchal skin foldOpen Targets
0.35Weak
osteoarthritis, kneeOpen Targets
0.34Weak
COVID-19Open Targets
0.29Weak
hemolysisOpen Targets
0.28Weak
PainOpen Targets
0.28Weak
skin cancerOpen Targets
0.28Weak
response to xenobiotic stimulusOpen Targets
0.28Weak
PancytopeniaOpen Targets
0.27Weak
diffuse lymphatic malformationOpen Targets
0.27Weak
lymphatic system diseaseOpen Targets
0.26Weak
Dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edemaUniProt
Lymphatic malformation 6UniProt
Pathogenic Variants120
NM_001142864.4(PIEZO1):c.6380C>T (p.Thr2127Met)Pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 2127
NM_001142864.4(PIEZO1):c.6058G>A (p.Ala2020Thr)Pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 2020
NM_001142864.4(PIEZO1):c.1792G>A (p.Val598Met)Pathogenic
Non-immune hydrops fetalis|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 598
NM_001142864.4(PIEZO1):c.7367G>A (p.Arg2456His)Pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided|PIEZO1-related disorder|Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema;Blood group, ER;Lymphatic malformation 6|Non-immune hydrops fetalis
β˜…β˜…β˜†β˜†2025β†’ Residue 2456
NM_001142864.4(PIEZO1):c.1536_1537del (p.Cys513fs)Pathogenic
Hydrops fetalis;Thickened nuchal skin fold|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 513
NM_001142864.4(PIEZO1):c.7477CTGGAG[3] (p.2493LE[3])Pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided|Lymphatic malformation 6|Blood group, ER;Lymphatic malformation 6;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|PIEZO1-related disorder
β˜…β˜…β˜†β˜†2025
NM_001142864.4(PIEZO1):c.6067C>G (p.Leu2023Val)Likely pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 2023
NM_001142864.4(PIEZO1):c.3490C>T (p.Arg1164Ter)Pathogenic
not provided|Lymphatic malformation 6
β˜…β˜…β˜†β˜†2025β†’ Residue 1164
NM_001142864.4(PIEZO1):c.1297-1G>ALikely pathogenic
Lymphatic malformation 6|not provided
β˜…β˜…β˜†β˜†2025
NM_001142864.4(PIEZO1):c.3373C>T (p.Gln1125Ter)Pathogenic
PIEZO1-related disorder|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 1125
NM_001142864.4(PIEZO1):c.5289C>G (p.Tyr1763Ter)Pathogenic
not provided|ER BLOOD GROUP SYSTEM, ER(a-b-)|Lymphatic malformation 6|PIEZO1-related disorder|Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema
β˜…β˜…β˜†β˜†2024β†’ Residue 1763
NM_001142864.4(PIEZO1):c.1361G>A (p.Trp454Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 454
NM_001142864.4(PIEZO1):c.6674T>G (p.Met2225Arg)Likely pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 2225
NM_001142864.4(PIEZO1):c.157del (p.Gln53fs)Likely pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 53
NM_001142864.4(PIEZO1):c.5290G>T (p.Glu1764Ter)Likely pathogenic
not provided|Lymphatic malformation 6
β˜…β˜…β˜†β˜†2024β†’ Residue 1764
NM_001142864.4(PIEZO1):c.6019A>C (p.Met2007Leu)Pathogenic
not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 2007
NM_001142864.4(PIEZO1):c.1264C>T (p.Gln422Ter)Pathogenic
not provided|Lymphatic malformation 6
β˜…β˜…β˜†β˜†2023β†’ Residue 422
NM_001142864.4(PIEZO1):c.1381C>T (p.Gln461Ter)Pathogenic
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema;Lymphatic malformation 6|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 461
NM_001142864.4(PIEZO1):c.6262C>G (p.Arg2088Gly)Likely pathogenic
not provided|PIEZO1-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 2088
NM_001142864.4(PIEZO1):c.4275_4278del (p.Ser1425fs)Pathogenic
Inborn genetic diseases|not provided|Lymphatic malformation 6
β˜…β˜…β˜†β˜†2023β†’ Residue 1425
View on ClinVar β†—
Related Genes
WDHD1Protein interaction100%MCM4Protein interaction100%TIMELESSProtein interaction86%TIPINProtein interaction86%TRPV4Protein interaction79%CHEK2Protein interaction74%
Tissue Expression6 tissues
Lung
100%
Bone Marrow
63%
Liver
48%
Ovary
22%
Heart
15%
Brain
5%
Gene Interaction Network
Click a node to explore
PIEZO1WDHD1MCM4TIMELESSTIPINTRPV4CHEK2
PROTEIN STRUCTURE
Preparing viewer…
PDB8ZU3 Β· 3.10 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.17LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.06 [0.96–1.17]
RankingsWhere PIEZO1 stands among ~20K protein-coding genes
  • #1,414of 20,598
    Most Researched266 Β· top 10%
  • #650of 5,498
    Most Pathogenic Variants120 Β· top quartile
  • #12,242of 17,882
    Most Constrained (LOEUF)1.17
Genes detectedPIEZO1
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Mechanosensing by Piezo1 and its implications for physiology and various pathologies.
PMID: 34781417
Biol Rev Camb Philos Soc Β· 2022
1.00
2
Piezo1 and its inhibitors: Overview and perspectives.
PMID: 38761789
Eur J Med Chem Β· 2024
0.90
3
Mechanisms of mechanotransduction and physiological roles of PIEZO channels.
PMID: 39251883
Nat Rev Mol Cell Biol Β· 2024
0.80
4
Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma.
PMID: 36181398
Cancer Commun (Lond) Β· 2022
0.70
5
PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocytes.
PMID: 38514773
Nat Biomed Eng Β· 2024
0.64